Month: June 2013

Greenestone Healthcare Corp. CEO Discusses Valuation for Canadian Medical Clinics

June 26, 2013 OneMedPlace Team 0

GreeneStone Healthcare Corp. (OTCBB: GRST) operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly under-serviced niches. Greenestone President and CEO Shawn Leon spoke with OneMedRadio about market opportunity for clinics in the unique Canadian healthcare system, and evolving valuation drivers in this space.

Metabiomics’ Exec: Test Can Be a Cheaper and More Accurate Alternative to Colonoscopies

June 25, 2013 OneMedPlace Team 0

Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivity in excess of 97%” and specificity “as high as 93%.” Metabiomics will present at the upcoming OneMedForumNY 2013 on June 27th.

Aptiv Solutions Executive Discusses the State of Mobile Health Technology Regulatory

June 23, 2013 OneMedPlace Team 0

OneMedRadio spoke with Cynthia Nolte, Director, Medical Device Regulatory Services for Aptiv Solutions, about the state of mobile health/health information technology regulatory, clinical trial design for mobile health technology, and what we can expect from future guidelines. The conclusions about regulating a rapidly evolving space — and the case studies that have pioneered this process — are intriguing, and indeed promising.

Functional Neuromodulation CEO: Deep Brain Stimulation a Treatment for Alzheimer’s Disease

June 18, 2013 OneMedPlace Team 0

Charlottesville, VA-based Functional Neuromodulation is conducting an advanced trial of the application of Deep Brain Stimulation (DBS) therapy as a supplement for current Alzheimer’s Disease treatments. OneMedRadio’s Matt Margolis spoke with Dan O’Connell, co-founder and CEO of Functional Neuromodulation, about the science behind applying Deep Brain Stimulation to Alzheimer’s Disease, its current clinical trial, the lack of venture capital for Alzheimer’s research, and the regulatory obstacles that Functional Neuromodulation will face in the future.

Okairos: Okay After All

June 5, 2013 OneMedPlace Team 0

On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.